Aztreonam/avibactam

Aztreonam/avibactam
Combination of
Aztreonamβ-lactam antibiotic
Avibactamβ-Lactamase inhibitor
Clinical data
Trade namesEmblaveo
ATC code
  • None
Legal status
Legal status
Identifiers
KEGG

Aztreonam/avibactam, sold under the brand name Emblaveo, is a combination of aztreonam, a β-lactam antibiotic, and avibactam, a β-Lactamase inhibitor, developed by AbbVie and Pfizer for aerobic Gram-negative infections.[2][3][4][5] Drug resistance to the combination has been reported.[6]

The combination was approved for medical use in the European Union in April 2024.[2][7]

  1. ^ Cite error: The named reference Emblaveo EPAR was invoked but never defined (see the help page).
  2. ^ a b c "Emblaveo Product information". Union Register of medicinal products. 22 April 2024. Retrieved 22 April 2024.
  3. ^ "Pipeline". AbbVie. Archived from the original on 25 November 2023. Retrieved 25 November 2023.
  4. ^ Sader, Helio S; Castanheira, Mariana; Kimbrough, John H; Kantro, Valerie; Mendes, Rodrigo E (22 March 2023). "Aztreonam/avibactam activity against a large collection of carbapenem-resistant Enterobacterales (CRE) collected in hospitals from Europe, Asia and Latin America (2019–21)". JAC-Antimicrobial Resistance. 5 (2): dlad032. doi:10.1093/jacamr/dlad032. ISSN 2632-1823. PMC 10032302. PMID 36968952.
  5. ^ Livermore, David M.; Mushtaq, Shazad; Vickers, Anna; Woodford, Neil (May 2023). "Activity of aztreonam/avibactam against metallo-β-lactamase-producing Enterobacterales from the UK: Impact of penicillin-binding protein-3 inserts and CMY-42 β-lactamase in Escherichia coli". International Journal of Antimicrobial Agents. 61 (5): 106776. doi:10.1016/j.ijantimicag.2023.106776. PMID 36893810. S2CID 257428399.
  6. ^ Nordmann, Patrice; Yao, Yancheng; Falgenhauer, Linda; Sadek, Mustafa; Imirzalioglu, Can; Chakraborty, Trinad (18 October 2021). "Recent Emergence of Aztreonam-Avibactam Resistance in NDM and OXA-48 Carbapenemase-Producing Escherichia coli in Germany". Antimicrobial Agents and Chemotherapy. 65 (11): e0109021. doi:10.1128/aac.01090-21. PMC 8522741. PMID 34424048. S2CID 237268078.
  7. ^ "European Commission Approves Pfizer's Emblaveo for Patients with Multidrug-Resistant Infections and Limited Treatment Options". Pfizer (Press release). 22 April 2024. Retrieved 22 April 2024.